<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2478">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402840</url>
  </required_header>
  <id_info>
    <org_study_id>2004963113</org_study_id>
    <nct_id>NCT04402840</nct_id>
  </id_info>
  <brief_title>Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <official_title>Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate&#xD;
      Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome&#xD;
      (ARDS) due to COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aim:&#xD;
&#xD;
      â€¢ To determine safety of stellate ganglion block (SGB) in ARDS&#xD;
&#xD;
      Secondary Aim:&#xD;
&#xD;
        -  To determine efficacy of SGB in slowing the progression of ARDS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events related to SGB</measure>
    <time_frame>3 Months</time_frame>
    <description>Adverse events that can atleast unlikely be attributed to SGB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Adverse events</measure>
    <time_frame>3 Months</time_frame>
    <description>All adverse events related to COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>3 Months</time_frame>
    <description>Death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of respiratory/ pulmonary function</measure>
    <time_frame>3 Months</time_frame>
    <description>Change from baseline clinical respiratory/pulmonary function as assessed by change in PF ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic criteria</measure>
    <time_frame>3 Months</time_frame>
    <description>Change from last imaging data obtained prior to SGB procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>3 Months</time_frame>
    <description>Change from baseline clinical cardiac function as assessed by improvement in arrhythmia as measured by standard of care ECG ( rate, rhythm and / or any aberrant electro physiological changes)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Stellate Ganglion Block (SGB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical Stellate ganglion block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stellate Ganglion Block</intervention_name>
    <description>The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.</description>
    <arm_group_label>Stellate Ganglion Block (SGB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 18 to 80&#xD;
&#xD;
          -  Subjects with PCR documented diagnosis of COVID-19 ARDS requiring critical care and&#xD;
             transfer to intensive care unit&#xD;
&#xD;
          -  Bilateral opacities consistent with pulmonary edema must be present and may be&#xD;
             detected on CT or chest radiograph&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with pre-existing cardiac failure&#xD;
&#xD;
          -  Hemodynamic Instability&#xD;
&#xD;
          -  Subject on Extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  Anatomical inability to do a stellate block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali R Rezai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Padma Tirumalai, PhD</last_name>
    <phone>3042934999</phone>
    <email>ptirumalai@hsc.wvu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>West Virginia University Rockefeller Neuroscience Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Padma Tirumalai, PhD</last_name>
      <phone>304-293-4999</phone>
      <email>ptirumalai@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Ali Rezai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Ali Rezai</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <keyword>Stellate Ganglion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

